The stock has a 36-month beta value of 1.36. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ETNB is 141.32M, and at present, short sellers hold a 9.90% of that float. On July 02, 2025, the average trading volume of ETNB was 2.06M shares.
ETNB) stock’s latest price update
The stock of 89bio Inc (NASDAQ: ETNB) has increased by 4.68% when compared to last closing price of $9.73. Despite this, the company has experienced a 4.35% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-06 that SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) — 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 61,100 shares of the Company’s common stock to three new employees (the “Inducement Grants”) on June 3, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
ETNB’s Market Performance
ETNB’s stock has risen by 4.35% in the past week, with a monthly rise of 0.74% and a quarterly rise of 49.89%. The volatility ratio for the week is 4.21% while the volatility levels for the last 30 days are 5.25% for 89bio Inc The simple moving average for the past 20 days is 1.66% for ETNB’s stock, with a 21.30% simple moving average for the past 200 days.
Analysts’ Opinion of ETNB
Many brokerage firms have already submitted their reports for ETNB stocks, with Goldman repeating the rating for ETNB by listing it as a “Neutral.” The predicted price for ETNB in the upcoming period, according to Goldman is $11 based on the research report published on March 14, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see ETNB reach a price target of $25. The rating they have provided for ETNB stocks is “Buy” according to the report published on March 13th, 2025.
ETNB Trading at 13.15% from the 50-Day Moving Average
After a stumble in the market that brought ETNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.98% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ETNB starting from Le-Nguyen Quoc, who sale 15,329 shares at the price of $5.95 back on Apr 15 ’25. After this action, Le-Nguyen Quoc now owns 328,323 shares of 89bio Inc, valued at $91,208 using the latest closing price.
Stock Fundamentals for ETNB
Current profitability levels for the company are sitting at:
- -19204.19 for the present operating margin
- 0.43 for the gross margin
The net margin for 89bio Inc stands at -18413.0. The total capital return value is set at -0.62. Equity return is now at value -69.30, with -61.26 for asset returns.
Based on 89bio Inc (ETNB), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -243.95. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -127.62.
Currently, EBITDA for the company is -384.66 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of 55583.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.03.
Conclusion
To sum up, 89bio Inc (ETNB) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
